5. Gentium ( GENT) is an Italian biopharmaceutical company focused on the development and manufacture of drugs for vascular diseases related to cancer and cancer treatment.

For full-year 2010, total revenue was $36 million, up from $15.2 million in 2009. Operating income was $6.7 million, compared with a loss of $6.8 million. Net income was $6.1 million, improving from a loss of $6.8 million.

Earnings per share were 40 cents, compared with a negative 45 cents per share in 2009. Operating cash flow was $12.2 million, compared with negative cash flows in 2009. The company has cash of $13 million and reduced debt in its books. The stock is trading at 11 times its estimated 2011 earnings and is expected to gain 62% in the next one year.

If you liked this article you might like

3 Materials & Construction Stocks Pushing The Industry Higher

RSI Alert: ICA Now Oversold

3 Stocks Dragging The Materials & Construction Industry Downward

5 Stocks Under $10 Making Big Moves

5 Stocks Under $10 Set to Soar